BUZZ-Australia's Cleo Diagnostics rises to near 2-month high on US approval for trial

Reuters
06/25
BUZZ-Australia's Cleo Diagnostics rises to near 2-month high on US approval for trial

** Shares of Cleo Diagnostics COV.AX rise as much as 17.7% to A$0.400, their highest level since May 5

** Stock set for its best day since April 14, if trends sustain

** The cancer diagnostics tests provider receives approval from U.S. National Cancer Institute to access blood samples from the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial

** Around 209,750 shares change hands, busiest day since May 19

** Stock up 4.2%, YTD

(Reporting by Keshav Singh Chundawat in Bengaluru)

((Keshav.SinghChundawat@thomsonreuters.com))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10